Where does Raze Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Raze Therapeutics, Inc. ranks #33,012 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Raze Therapeutics, Inc. hold?

Raze Therapeutics, Inc. holds 8 US utility patents granted between 2021 and 2025, spanning 4 technology areas.

What is Raze Therapeutics, Inc.'s Innovation Score?

Raze Therapeutics, Inc. has an Innovation Score of 30.9 out of 100 (36th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Raze Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Raze Therapeutics, Inc..

What does claim depth mean for Raze Therapeutics, Inc.'s patents?

Raze Therapeutics, Inc.'s patents average 16.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Raze Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Raze Therapeutics, Inc.

Q: What technology areas does Raze Therapeutics, Inc. focus on?

Raze Therapeutics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 8 patents. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 8 granted patents across 4 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Raze ranks #33,012 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 4 technology areas.

#33,012
of 49,997 US assignees by volume: 36th percentile
by Innovation Score (30.9/100): 16.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R33012 · US Corporation #33,012 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 8 grants
MID-PACK #33,012/49,997
PHOTO-FINISH Ramscor
CPC-NARROW A61P · 4 areas
INNOV-THIN 30.9/100
CLAIMS-RICH 16.0 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Ramscor, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Raze Therapeutics · this assignee

31
3D Lighting… · lowest

7

What this shows Raze's Innovation Score is 30.9/100 (36th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Raze's grants concentrate

Raze Therapeutics, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (3 grants) versus a trough of 1 in 2023. By volume, Raze sits between Ramscor, Inc. and Recorded Future, Inc..

Raze's three-year grant acceleration

Raze Therapeutics, Inc. shows 3 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Ramscor

8
Raptor

8
Raute Oyj

8
Raycast Systems

8
Revision Optics

8
Reckitt Benckiser…

8
Recommind

8
Recorded Future

8
Raze Therapeutics ◀

8

What this shows Raze holds 8 patents at rank #33,052, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Raze

By rank, the assignees closest to #33,052 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Raze's primary technology class.

Raze's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 36th percentile higher than 36% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Raze Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	3	37.5%
2022	2	25.0%
2023	1	12.5%
2025partial year	2	25.0%

Which technologies does Raze Therapeutics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 8

C07D - Heterocyclic Compounds 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

C07C - Acyclic OR Carbocyclic Compounds 1

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#33,012

of 49,997 tracked assignees

Innovation Score

30.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Raze Therapeutics, Inc.'s patent record in context - here's where to go next.

Raze Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #33,012 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Raze Therapeutics, Inc. against Ramscor, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.